

<b>NCT ID</b>	NCT06788171
<b>Title</b>	PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM
<b>Phase</b>	Phase 2
<b>Date Added</b>	2025-03-25
<b>Location</b>	China
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Not yet recruiting
<b>Drugs</b>	
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT03650348
<b>Title</b>	PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
<b>Phase</b>	Phase 1
<b>Date Added</b>	2018-08-28
<b>Location</b>	California, United States Louisiana, United States New York, United States Ohio, United States Texas, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	PRS-343 in Combination with Atezolizumab, Tecentriq
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT01697371
<b>Title</b>	Proton Therapy in the Treatment of Liver Metastases
<b>Phase</b>	Not Applicable
<b>Date Added</b>	2012-10-02
<b>Location</b>	California, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No
<b>Status</b>	Recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT06120127
<b>Title</b>	Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
<b>Phase</b>	Phase 2
<b>Date Added</b>	2023-11-07
<b>Location</b>	China
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Chemotherapy, PD-1 antibody
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT04117087
<b>Title</b>	Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer

<b>Phase</b>	Phase 1
<b>Date Added</b>	2019-10-07
<b>Location</b>	Maryland, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Ipilimumab, Nivolumab, Opdivo, Yervoy
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT06300463
<b>Title</b>	Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
<b>Phase</b>	Phase 2
<b>Date Added</b>	2024-03-08
<b>Location</b>	New York, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	AGEN1423, Balstilimab, Botensilimab
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT03868228
<b>Title</b>	PIPAC for the Treatment of Colorectal Peritoneal Metastases
<b>Phase</b>	Phase 1
<b>Date Added</b>	2019-03-11
<b>Location</b>	United Kingdom
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT04708470
<b>Title</b>	Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2021-01-14
<b>Location</b>	Maryland, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Bintrafusp alfa, Entinostat, NHS-IL12
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT06149481
<b>Title</b>	Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2023-11-29
<b>Location</b>	Maryland, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes

<b>Status</b>	Recruiting
<b>Drugs</b>	N-803, Retifanlimab, SX-682
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT02484404
<b>Title</b>	Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2015-06-29
<b>Location</b>	Maryland, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Cediranib, durvalumab, Olaparib
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp